Riga, undefined

By Yan-Voldemar Ozol, Administrator


Average Co-Inventor Count = 9.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1976

Loading Chart...
1 patent (USPTO):Explore Patents

Title: By Yan-Voldemar Ozol: A Pioneer in Antiepileptic Compounds

Introduction

By Yan-Voldemar Ozol is an accomplished inventor and administrator based in Riga, Latvia. He has made significant contributions to the field of medicinal chemistry, particularly in the development of antiepileptic compounds. His innovative work has led to the creation of a patent that showcases his expertise and dedication to advancing medical science.

Latest Patents

Ozol holds a patent for a methylamino derivative of 2-ethylindandione-1,3, which includes hydrochloride forms of antiepileptic compounds. The formula is designed to provide effective treatment options for epilepsy, demonstrating his commitment to improving patient outcomes. This patent is a testament to his innovative approach in the pharmaceutical industry, with a focus on creating compounds that can significantly impact the lives of those affected by epilepsy. He has 1 patent to his name.

Career Highlights

Ozol is currently affiliated with the Institut Organicheskogo Sinteza, where he continues to engage in groundbreaking research. His role as an administrator allows him to oversee various projects and collaborate with other experts in the field. His career is marked by a dedication to scientific advancement and a passion for developing new therapeutic solutions.

Collaborations

Throughout his career, Ozol has worked alongside notable colleagues, including Gustav Yanovich Vanags, who is now deceased, and Yan-Voldemar Y Ozol. These collaborations have enriched his research and contributed to the success of his projects.

Conclusion

By Yan-Voldemar Ozol is a distinguished inventor whose work in antiepileptic compounds has made a lasting impact on the field of medicinal chemistry. His innovative spirit and dedication to research continue to inspire future advancements in the treatment of epilepsy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…